The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
Por:
Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.
Publicada:
1 ene 2023
Ahead of Print:
26 ene 2023
Resumen:
Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society. Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included. Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at L 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response. Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis. Copyright © 2023 Maravilla-Herrera, Merino, Alfonso Zamora, Balea Filgueiras, Carrascosa Carrillo, Delgado Sánchez, Dolz Sinisterra, García-Ruiz, Herranz Pinto, Manfredi, Martínez Olmos, Morales de los Ríos Luna, Puig, Ros and Hidalgo-Vega.
Filiaciones:
Maravilla-Herrera P.:
Department of Health Outcomes Research, Weber, Madrid, Spain
Merino M.:
Department of Health Outcomes Research, Weber, Madrid, Spain
Alfonso Zamora S.:
Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain
Balea Filgueiras J.:
Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain
Carrascosa Carrillo J.M.:
Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain
Delgado Sánchez O.:
Department of Management, Spanish Society of Hospital Pharmacy (SEFH), Madrid, Spain
Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain
Dolz Sinisterra F.:
Department of Management, Doctor Peset University Hospital, Valencia, Spain
García-Ruiz A.:
Health Economics and Rational Use of Medicines, Department of Pharmacology and Clinical Therapeutics, Biomedical Research Institute of Malaga (IBIMA), University of Malaga, Malaga, Spain
Herranz Pinto P.:
Department of Dermatology, La Paz University Hospital, Madrid, Spain
Manfredi A.:
Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain
Martínez Olmos J.:
Andalusian Public Health School (EASP), Granada, Spain
Morales de los Ríos Luna P.:
Department of Nursing, Gregorio Marañón University Hospital, Madrid, Spain
Puig L.:
Department of Dermatology, Santa Creu i Sant Pau Hospital, Barcelona, Spain
Universitat Autònoma de Barcelona, Barcelona, Spain
Ros S.:
Psychologist, Departments of Dermatology and Rheumatology, and Cardiac Transplant Unit, Santa Creu i Sant Pau Hospital, Barcelona, Spain
Hidalgo-Vega Á.:
Department of Economic Analysis and Finances, University of Castilla-La Mancha, Toledo, Spain
Fundación Weber, Madrid, Spain
gold, Green Published, All Open Access; Gold
|